Birdwatch Note
2024-09-22 12:32:50 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING
旧来型抗がん剤の延命効果も証明されています https://doi.org/10.1016/S0140-6736(00)02034-1 https://doi.org/10.1016/S1470-2045(08)70035-4 https://doi.org/10.1056/NEJM199504063321401 https://doi.org/10.1056/NEJMoa072252 がん死亡減少の半分の原因は化学療法を含むがん治療の進歩によるものです https://doi.org/10.1158/0008-5472.CAN-07-6611 https://en.wikipedia.org/wiki/Vincent_T._DeVita 主流のがん治療は劇的に進歩しています https://news.yahoo.co.jp/expert/articles/1b191a2ed5889e97d4311826f130aa016629b2a8 https://doi.org/10.1016/j.ejca.2017.01.035 年齢調整死亡率は減少しており日本はG7の中でも最も優秀です https://data.oecd.org/chart/7hLT https://data.oecd.org/healthstat/deaths-from-cancer.htm 科学的根拠に基づかない主張の目的は偽医療への誘導です。 日本人が欧米事情等に疎いことは昔から偽医療利権に悪用されています https://youtu.be/nySPY7eH9IU https://cancer.jpn.org/static/fake_medicine.html https://cancer.jpn.org/static/ota_h_405_unconventional_cancer_treatments.html 代替医療にがんの治療効果はありません https://doi.org/10.1093/jnci/djx145 https://doi.org/10.1001/jamaoncol.2018.2487 米国は1991年から国を挙げて30年以上研究しましたが、がんに効果のある代替医療は未だに見つかっていません https://en.wikipedia.org/wiki/National_Center_for_Complementary_and_Integrative_Health
Written by EE7192EF0B1C47D8A3430C3E070DA2A0BFAA58717F9133404318E9D7666B1A00
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1837735682934296670
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1837832426732900838
- noteId - 1837832426732900838
- participantId -
- noteAuthorParticipantId - EE7192EF0B1C47D8A3430C3E070DA2A0BFAA58717F9133404318E9D7666B1A00 Participant Details
- createdAtMillis - 1727008370464
- tweetId - 1837735682934296670
- classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 1
- misleadingManipulatedMedia - 0
- misleadingOutdatedInformation - 0
- misleadingMissingImportantContext - 1
- misleadingUnverifiedClaimAsFact - 1
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- 旧来型抗がん剤の延命効果も証明されています https://doi.org/10.1016/S0140-6736(00)02034-1 https://doi.org/10.1016/S1470-2045(08)70035-4 https://doi.org/10.1056/NEJM199504063321401 https://doi.org/10.1056/NEJMoa072252 がん死亡減少の半分の原因は化学療法を含むがん治療の進歩によるものです https://doi.org/10.1158/0008-5472.CAN-07-6611 https://en.wikipedia.org/wiki/Vincent_T._DeVita 主流のがん治療は劇的に進歩しています https://news.yahoo.co.jp/expert/articles/1b191a2ed5889e97d4311826f130aa016629b2a8 https://doi.org/10.1016/j.ejca.2017.01.035 年齢調整死亡率は減少しており日本はG7の中でも最も優秀です https://data.oecd.org/chart/7hLT https://data.oecd.org/healthstat/deaths-from-cancer.htm 科学的根拠に基づかない主張の目的は偽医療への誘導です。 日本人が欧米事情等に疎いことは昔から偽医療利権に悪用されています https://youtu.be/nySPY7eH9IU https://cancer.jpn.org/static/fake_medicine.html https://cancer.jpn.org/static/ota_h_405_unconventional_cancer_treatments.html 代替医療にがんの治療効果はありません https://doi.org/10.1093/jnci/djx145 https://doi.org/10.1001/jamaoncol.2018.2487 米国は1991年から国を挙げて30年以上研究しましたが、がんに効果のある代替医療は未だに見つかっていません https://en.wikipedia.org/wiki/National_Center_for_Complementary_and_Integrative_Health
Note Ratings
rated at | rated by | |
2024-09-29 16:54:40 -0500 | Rating Details | |
2024-09-26 19:16:52 -0500 | Rating Details | |
2024-09-23 10:17:53 -0500 | Rating Details | |
2024-09-23 08:22:30 -0500 | Rating Details | |
2024-09-23 07:20:11 -0500 | Rating Details | |
2024-09-23 06:43:09 -0500 | Rating Details | |
2024-09-23 06:10:59 -0500 | Rating Details | |
2024-09-23 05:24:14 -0500 | Rating Details | |
2024-09-23 04:13:02 -0500 | Rating Details | |
2024-09-23 03:37:41 -0500 | Rating Details | |
2024-09-23 02:47:05 -0500 | Rating Details | |
2024-09-23 00:54:14 -0500 | Rating Details | |
2024-09-23 00:53:37 -0500 | Rating Details | |
2024-09-23 00:36:36 -0500 | Rating Details | |
2024-09-22 23:58:12 -0500 | Rating Details | |
2024-09-22 23:18:38 -0500 | Rating Details | |
2024-09-22 22:18:39 -0500 | Rating Details | |
2024-09-22 20:59:52 -0500 | Rating Details | |
2024-09-22 20:25:47 -0500 | Rating Details | |
2024-09-22 20:14:37 -0500 | Rating Details | |
2024-09-22 20:08:32 -0500 | Rating Details | |
2024-09-22 19:03:07 -0500 | Rating Details | |
2024-09-22 18:31:17 -0500 | Rating Details | |
2024-09-22 16:34:41 -0500 | Rating Details | |
2024-09-22 15:53:04 -0500 | Rating Details | |
2024-09-22 15:45:18 -0500 | Rating Details | |
2024-09-22 15:23:52 -0500 | Rating Details | |
2024-09-22 13:33:49 -0500 | Rating Details | |
2024-09-22 13:28:38 -0500 | Rating Details | |
2024-09-22 13:09:42 -0500 | Rating Details | |
2024-09-22 13:02:34 -0500 | Rating Details | |
2024-09-22 12:05:28 -0500 | Rating Details | |
2024-09-22 11:56:05 -0500 | Rating Details | |
2024-09-22 11:53:13 -0500 | Rating Details | |
2024-09-22 11:42:33 -0500 | Rating Details | |
2024-09-22 11:36:50 -0500 | Rating Details | |
2024-09-22 11:29:23 -0500 | Rating Details | |
2024-09-22 11:22:07 -0500 | Rating Details | |
2024-09-22 11:00:09 -0500 | Rating Details | |
2024-09-22 10:39:02 -0500 | Rating Details | |
2024-09-22 10:32:43 -0500 | Rating Details | |
2024-09-22 10:19:55 -0500 | Rating Details | |
2024-09-22 10:19:14 -0500 | Rating Details | |
2024-09-22 10:12:20 -0500 | Rating Details | |
2024-09-22 10:11:19 -0500 | Rating Details | |
2024-09-22 10:00:37 -0500 | Rating Details | |
2024-09-22 10:00:09 -0500 | Rating Details | |
2024-09-22 09:52:30 -0500 | Rating Details | |
2024-09-22 09:51:16 -0500 | Rating Details | |
2024-09-22 09:20:53 -0500 | Rating Details | |
2024-09-22 09:20:08 -0500 | Rating Details | |
2024-09-22 09:09:44 -0500 | Rating Details | |
2024-09-22 09:09:06 -0500 | Rating Details | |
2024-09-22 09:07:51 -0500 | Rating Details | |
2024-09-22 09:05:24 -0500 | Rating Details | |
2024-09-22 09:01:37 -0500 | Rating Details | |
2024-09-22 08:59:07 -0500 | Rating Details | |
2024-09-22 08:48:35 -0500 | Rating Details | |
2024-09-22 08:45:45 -0500 | Rating Details | |
2024-09-22 08:40:25 -0500 | Rating Details | |
2024-09-22 08:39:32 -0500 | Rating Details | |
2024-09-22 08:39:09 -0500 | Rating Details | |
2024-09-22 08:36:43 -0500 | Rating Details | |
2024-09-22 08:31:54 -0500 | Rating Details | |
2024-09-22 08:30:48 -0500 | Rating Details | |
2024-09-22 08:29:27 -0500 | Rating Details | |
2024-09-22 08:27:45 -0500 | Rating Details | |
2024-09-22 08:26:19 -0500 | Rating Details | |
2024-09-22 08:23:24 -0500 | Rating Details | |
2024-09-22 08:18:25 -0500 | Rating Details | |
2024-09-22 08:17:08 -0500 | Rating Details | |
2024-09-22 08:16:31 -0500 | Rating Details | |
2024-09-22 08:15:53 -0500 | Rating Details | |
2024-09-22 08:14:49 -0500 | Rating Details | |
2024-09-22 08:14:45 -0500 | Rating Details | |
2024-09-22 08:14:11 -0500 | Rating Details | |
2024-09-22 08:14:08 -0500 | Rating Details | |
2024-09-22 08:13:00 -0500 | Rating Details | |
2024-09-22 08:12:38 -0500 | Rating Details | |
2024-09-22 08:12:25 -0500 | Rating Details | |
2024-09-22 08:10:39 -0500 | Rating Details | |
2024-09-22 08:09:18 -0500 | Rating Details | |
2024-09-22 08:03:39 -0500 | Rating Details | |
2024-09-22 07:45:15 -0500 | Rating Details | |
2024-09-22 07:41:55 -0500 | Rating Details | |
2024-10-03 13:30:47 -0500 | Rating Details |